These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 2480328

  • 1. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping.
    Ohlin M, Broliden PA, Danielsson L, Wahren B, Rosen J, Jondal M, Borrebaeck CA.
    Immunology; 1989 Nov; 68(3):325-31. PubMed ID: 2480328
    [Abstract] [Full Text] [Related]

  • 2. Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors.
    Chin LT, Hinkula J, Levi M, Ohlin M, Wahren B, Borrebaeck CA.
    Immunology; 1994 Mar; 81(3):428-34. PubMed ID: 7515847
    [Abstract] [Full Text] [Related]

  • 3. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R.
    Virology; 1997 Aug 18; 235(1):26-39. PubMed ID: 9300034
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus.
    Ohlin M, Sundqvist VA, Gilljam G, Rudén U, Gombert FO, Wahren B, Borrebaeck CA.
    Clin Exp Immunol; 1991 Jun 18; 84(3):508-14. PubMed ID: 1710548
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L, Nara P, Dunlop N, Putney S, Morein B.
    Biotechnol Ther; 1993 Jun 18; 4(3-4):145-61. PubMed ID: 8292967
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA.
    J Immunol; 1993 Jun 15; 150(12):5647-65. PubMed ID: 8515081
    [Abstract] [Full Text] [Related]

  • 10. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
    Pincus SH, Messer KG, Nara PL, Blattner WA, Colclough G, Reitz M.
    J Clin Invest; 1994 Jun 15; 93(6):2505-13. PubMed ID: 7515393
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
    Pasquali JL, Kieny MP, Kolbe H, Christmann D, Knapp AM.
    AIDS Res Hum Retroviruses; 1990 Sep 15; 6(9):1107-13. PubMed ID: 1702300
    [Abstract] [Full Text] [Related]

  • 12. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes.
    Zaghouani H, Goldstein D, Shah H, Anderson S, Lacroix M, Dionne G, Kennedy R, Bona C.
    Proc Natl Acad Sci U S A; 1991 Jul 01; 88(13):5645-9. PubMed ID: 2062842
    [Abstract] [Full Text] [Related]

  • 13. Characterization and large production of human monoclonal antibodies against the HIV-1 envelope.
    Boyer V, Broly H, Souche S, Madaule P, Rossier J, Zagury D, Desgranges C.
    Clin Exp Immunol; 1991 Mar 01; 83(3):452-9. PubMed ID: 1706239
    [Abstract] [Full Text] [Related]

  • 14. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
    Pincus SH, Cole RL, Hersh EM, Lake D, Masuho Y, Durda PJ, McClure J.
    J Immunol; 1991 Jun 15; 146(12):4315-24. PubMed ID: 1710247
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
    Ravanshad M, Sabahi F, Mahboudi F, Kazemnejad A.
    Saudi Med J; 2006 Jan 15; 27(1):31-6. PubMed ID: 16432590
    [Abstract] [Full Text] [Related]

  • 16. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH, Messer KG, Hu SL.
    J Clin Invest; 1994 Jan 15; 93(1):140-6. PubMed ID: 8282780
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates.
    Nakamura GR, Byrn R, Rosenthal K, Porter JP, Hobbs MR, Riddle L, Eastman DJ, Dowbenko D, Gregory T, Fendly BM.
    AIDS Res Hum Retroviruses; 1992 Nov 15; 8(11):1875-85. PubMed ID: 1283308
    [Abstract] [Full Text] [Related]

  • 18. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades.
    Zhang MY, Shu Y, Sidorov I, Dimitrov DS.
    Antiviral Res; 2004 Mar 15; 61(3):161-4. PubMed ID: 15168796
    [Abstract] [Full Text] [Related]

  • 19. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    VanCott TC, Bethke FR, Burke DS, Redfield RR, Birx DL.
    J Immunol; 1995 Oct 15; 155(8):4100-10. PubMed ID: 7561123
    [Abstract] [Full Text] [Related]

  • 20. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41.
    Viveros M, Dickey C, Cotropia JP, Gevorkian G, Larralde C, Broliden K, Levi M, Burgess A, Cao C, Weiner DB, Agadjanyan MG, Ugen KE.
    Virology; 2000 Apr 25; 270(1):135-45. PubMed ID: 10772986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.